China Shineway Pharmaceutical Group Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

China Shineway Pharmaceutical Group non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Zhenjiang Li	Co-Founder & Executive Chairman	22.1yrs	CN¥25.64m	72.39% € 582.6m
Yunxia Xin	Co-Founder & Executive Director	20.3yrs	CN¥13.20m	0.071% € 575.4k
Huimin Li	Executive Director	20.3yrs	CN¥2.12m	0.14% € 1.1m
Shun Fai Liu	Independent Non-Executive Director	3yrs	CN¥142.00k	Nessun dato
Guihua Wang	Independent Non-Executive Director	1.6yrs	CN¥106.00k	Nessun dato
Wencheng Zhou	Non-Executive Director	4.1yrs	CN¥142.00k	Nessun dato
Yat On Yew	Independent Non-Executive Director	2.1yrs	CN¥142.00k	Nessun dato

4.1yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di C1S sono considerati esperti (durata media dell'incarico 4.1 anni).

China Shineway Pharmaceutical Group Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024

China Shineway Pharmaceutical Group Limited Announces Resignation of Liu Tiejun as Executive Director, Effective 1 November 2023

Less than half of directors are independent

China Shineway Pharmaceutical Group Limited Announces Board Changes

China Shineway Pharmaceutical Group Limited Announces Board and Committee Changes

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 27, 2022

Recent updates

Investor sentiment improves as stock rises 16%

First half 2024 earnings released: EPS: CN¥0.83 (vs CN¥0.65 in 1H 2023)

China Shineway Pharmaceutical Group Limited Announces Second Interim Dividend in Respect of the Fiscal Year Ending December 31, 2024, Payable on September 27, 2024

China Shineway Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022)

Upcoming dividend of HK$0.46 per share

Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022)

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 17%

China Shineway Pharmaceutical Group Limited Announces Resignation of Liu Tiejun as Executive Director, Effective 1 November 2023

Upcoming dividend of HK$0.12 per share at 5.9% yield

First half 2023 earnings released: EPS: CN¥0.65 (vs CN¥0.44 in 1H 2022)

China Shineway Pharmaceutical Group Limited Proposes Second Interim Dividend in Respect of the Fiscal Year 2023, Payable on 29 September 2023

China Shineway Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.74 in FY 2021)

Upcoming dividend of HK$0.35 per share at 5.6% yield

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.74 in FY 2021)

Less than half of directors are independent

China Shineway Pharmaceutical Group Limited Announces Board Changes

China Shineway Pharmaceutical Group Limited Announces Board and Committee Changes

Upcoming dividend of HK$0.13 per share

First half 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.41 in 1H 2021)

China Shineway Pharmaceutical Group Limited Announces Dividend for the Six Months Ended 30 June 2022, Payable on 29 September 2022

China Shineway Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 30, 2022

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.39 in FY 2020)

Upcoming dividend of HK$0.26 per share

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 27, 2022

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.39 in FY 2020)

Shineway Pharmaceutical Group Limited Resolves to Declare Interim Dividend of the Year Ending 31 December 2022, Payable on 18 May 2022

First half 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 1H 2020)

Investor sentiment improved over the past week

Upcoming dividend of HK$0.25 per share

Full year 2020 earnings released: EPS CN¥0.39 (vs CN¥0.64 in FY 2019)

China Shineway Pharmaceutical Group Limited Proposes Final Dividend, Payable on 17 June 2021

Full year 2020 earnings released: EPS CN¥0.39 (vs CN¥0.64 in FY 2019)

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day high: €0.65

New 90-day high: €0.60

New 90-day high: €0.58

China Shineway Pharmaceutical Group Limited Announces Committees Appointment

New 90-day low: €0.54

First half earnings released

First half earnings released

China Shineway Pharmaceutical Group Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day low - €0.55

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media

Età media